medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2023, Number 1

<< Back Next >>

Rev Med UAS 2023; 13 (1)

Candiduria y COVID-19: Microbiological characteristics and associated factors

Pacheco-Sánchez KA, Dehesa-López E, García-Vazquez RA, Mo-Ye G, Garay-Dixon YMA, Gutiérrez-Arzapalo PY

Language: Spanish
References: 20
Page: 15-26
PDF size: 223.07 Kb.


ABSTRACT

Objetives: To determine the microbiological characteristics and associated factors and prognosis of Candiduria in patients hospitalized for COVID-19 at the Hospital Civil de Culiacán. Material and methods: Observational, retrospective, longitudinal study. Type of study: Retrospective cohort conducted at the Hospital Civil de Culiacán, México. Patients older than 18 years hospitalized with a diagnosis of COVID-19 were included; pregnant women were excluded and patients with incomplete collection of the variables studied were eliminated. Results: Of the 341 patients hospitalized for COVID-19, 14.4% presented candiduria, 51% were female, with a mean age of 61.43 years. Candida albicans was the most isolated species with 57.1% of the cases. The use of steroids (OR 3.88) and antibiotics (OR 5.16) were factors associated with the presence of candiduria. Regarding mortality, age (OR 1.051), acute kidney injury (OR 7.302) and candiduria (OR 3.89) were found to be associated risk factors, while the use of steroids (OR 0.48) significantly reduced the risk. mortality risk. Conclusions: Candiduria is a frequent mycosis in hospitalized patients. In our hospital, a frequency of 14.4% was demonstrated; the associated risk factors are similar to studies previously conducted in patients hospitalized for COVID- 19 or other causes. The importance of the study is directed to the control of risk factors, in order to reduce complications and their association with mortality.


REFERENCES

  1. Bonifaz A, Montelongo JA, González GM,Treviño R, Flores A., et al. Evaluación deMALDI-TOF MS para la identificación de levaduraspatógenas oportunistas en muestrasclínicas. Rev Chilena Infectol 2019; 36(6): 790-793

  2. Kidd S, Halliday C, Alexiou H, Ellis D. Descriptionof medical fungi. Third Edition. Pfizer.2016. Pp 34 - 48.

  3. Jimenez G, Casanovas I, Gutierrez M, VazquezF, Sorlózano A, et al. Candiduria en pacienteshospitalizados: etiología, sensibilidada los fármacos antifúngicos y factoresde riesgo. Rev Esp Quimioter 2018;31(4):323-328

  4. Zamora KG, Barboza K, Vergara MA, VenturaR, Silva H. Frecuencia y susceptibilidadantifúngica de Candida spp. (No albicans)aislada de pacientes de unidades de cuidadoscríticos de un hospital de tercer nivel delnorte de Perú. Horiz Med (Lima) 2020;20(4):e 1230.

  5. Sánchez JM, Solorzano A, Navarro JM, GutierrezJ. Evolución de la resistencia a antibióticosde microorganismos causantes deinfecciones del tracto urinario: un estudio devigilancia epidemiológica de 4 años en poblaciónhospitalaria. Rev Clin Esp. 2018.

  6. Alfouzan WA, Dhar R. Candiduria: Evidence-based approach to management,¿are we there yet? J Mycol Med. 2017; 27:293—302

  7. Gutierrez R, Ortiz DC, Pena P. Identificacióndefinitiva de levaduras del género Candida:Métodos comerciales. OPS. 2020. BuenosAires, Argentina.

  8. Maldonado I, Arechavala A, Guelfand L, RellosoS, Garbasz C. Infecciones urinarias nosocomialespor levaduras. Estudio multicéntrico de 14hospitales de la red de micología de la CiudadAutónoma de Buenos Aires. Rev Iberoam Micol.2016. Arenas R. Candidosis (candidiasis) en: MicologíaMédica Ilustrada. Arenas R. 5ta edición.McGrawHill. 2014. Pp. 240-260.

  9. Gajdács M, Dóczi I, Ábrok M, Lázár A,Burián K. Epidemiology of candiduria andCandida urinary tract infection in inpatientsand outpatients: result from a 10-year retrospectivesurvey. Cent European J Urol.2019; 72: 209-214

  10. Whiteway M, Bachewich C. Morphogenesisin Candida albicans. Ann Rev Microbiol2007; 61:529-53.

  11. Kane L, Muzevich K. Micafungin in the treatmentof candiduria: A case series. MedicalMycol Case Rep. 2016; 11: 5–8.

  12. Song G, Liang G, Liu W. Fungal Co-infectionsAssociated with Global COVID-19 Pandemic:A Clinical and Diagnostic Perspectivefrom China. Mycopath. 2020 185:599–606.

  13. Jacobs D, Dilworth T, Beyda N, Casapao A,Bowers D. Overtreatment of AsyntomaticCandiduria among Hospitalized Patients: aMulti-institutional Study. AntimicrobAgents Chemother. 2018; 62 (1): e01464-17.

  14. Bougnoux ME, Kac G, Aegerter P, d’EnfertC, Fagon JY. Candidemia and candiduria incritically ill patients admitted to intensivecare units in France: incidence, molecular diversity,management and outcome. IntensCare Med 2008; 34:292-9.

  15. Huang S, Septimus E, Hayden MK, KleinmanK, Sturtevant J, Avery TR et al. Effect ofbody surface decolonisation on bacteriuriaand candiduria in intensive care units: ananalysis of a cluster-randomised trial. LancetInfect Dis 2016; 16: 70–7

  16. Gangneux JP, Dannaoui E, Fekkar A, Luyt CE,Botterel F, Prost N et al. Fungal infections inmechanically ventilated patients with COVID-19 during the first wave: the French multicentreMYCOVID study. Lancet Respir Med 2022; 10:180–90.

  17. Nebreda T, Miguel MA, March GA, Puente L,Cantón E, Martinez AM et al. Infección bacteriana/fúngica en pacientes con COVID-19 ingresadosen un hospital de tercer nivel deCastilla y León, España. Enferm. Infecc. Microbiol.Clin. 2020; 11: 003

  18. Goncalves SS, Souza AC, Chowdhary A, MeisJF, Colombo AL. Epidemiology and molecularmechanisms of antifungal resistance in Candidaand Aspergillus. Mycoses 2016; 59:198-219.

  19. Pfaller MA, Castanheira M. Nosocomial candidiasis:antifungal stewardship and the importanceof rapid diagnosis. Med Mycol. 2016;54(1): 1-22.

  20. Melgis PSM, Dias HSH, Basili DL, Tadano T,Khales ASK, Dutra V, et el. Epidemiologicalprofile of patients hospitalized with candiduriain the Central-Western region of Brazil. RevIberoam Micol. 2019;36(4):175–180




2020     |     www.medigraphic.com